Prenetics Global Limited has officially terminated its bitcoin purchasing program, opting instead to channel its capital and strategic efforts towards IM8, a burgeoning consumer health and longevity brand co-founded by football superstar David Beckham.
The Nasdaq-listed health sciences company disclosed that it stopped daily bitcoin purchases as of December 4, following a board resolution, and will cease all future cryptocurrency acquisitions. Despite this strategy shift, Prenetics will maintain its existing holdings of 510 bitcoin as a treasury reserve asset but will not invest additional capital into expanding this position.
This decision represents a significant departure from a strategy the company embraced earlier this year, during a period of increasing interest among public firms in accumulating bitcoin as a tangible asset amid a bullish market. Recently, however, this trend has slowed due to weakening cryptocurrency prices and a renewed focus on core business operations among investors.
Prenetics emphasized that the pivot is driven by the rapid expansion of IM8, which it heralds as the fastest-growing supplement brand in the industry’s history. Since its launch, IM8 has surpassed $100 million in annualized recurring revenue merely 11 months in, with projections estimating revenue growth to between $180 million and $200 million by fiscal year 2026.
“The phenomenal success of IM8 has exceeded all expectations, and we have scaled much faster than anticipated,” said Danny Yeung, Prenetics’ CEO and co-founder. He further stated that the management team and board unanimously agreed that concentrating resources on IM8 represents the most promising avenue for delivering long-term shareholder value.
Financially, Prenetics remains in a robust position, boasting over $70 million in cash and cash equivalents and zero debt. With its existing bitcoin holdings intact, the company indicates that its strong balance sheet affords it the flexibility required to fund the next phase of IM8’s growth internally, without dependence on external financing.
Under this revised capital allocation strategy, Prenetics will exclusively direct funds toward IM8’s operations and expansion. This includes efforts in product development, brand marketing, talent acquisition, working capital, and international growth initiatives. The shift exemplifies an aim to refine strategic clarity and strengthen governance practices.
IM8, which aims to simplify daily health routines with an all-in-one nutritional supplement, is being aggressively marketed with endorsements from Beckham and world-renowned tennis player Aryna Sabalenka. Prenetics has leaned heavily into celebrity endorsements as it scales its operations globally.
This strategic reassessment comes amidst a challenging landscape for bitcoin, which has encountered significant headwinds. The digital currency has struggled to regain kinetic energy following a sharp decline earlier this year, leading many companies with crypto-centric treasury strategies to experience pressure on their share prices.
While management had previously highlighted potential synergies between healthcare innovation and blockchain technology during the announcement of its bitcoin accumulation strategy in June, the discourse has since shifted towards a more traditional focus on operational execution, revenue growth, and consumer demand.
Though bitcoin will remain on Prenetics’ balance sheet, the company clarified that it will no longer be central to its capital allocation plans. Following the announcement, shares of Prenetics showed minimal movement, trading at around $16.42.
As of now, bitcoin is trading at $88,626, reflecting a 1% increase over the last 24 hours with a trading volume of $39 billion, leading to a market capitalization of approximately $1.77 trillion. The digital asset is currently near its weekly price range, just 1% below the seven-day high and 2% above the seven-day low, with a circulating supply of nearly 19.97 million BTC.
